Mineralys Therapeutics (Nasdaq: MLYS) announced on May 5, 2026 that its Compensation Committee granted inducement equity awards to two new non-executive employees.
The grants include 29,760 stock options and 22,320 restricted stock units under the 2025 Employment Inducement Incentive Award Plan, with vesting beginning May 4, 2026 and scheduled over four years. Awards were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
Key Figures
Current price:$29.28Inducement stock options:29,760 sharesInducement RSUs:22,320 shares+5 more
8 metrics
Current price$29.28Prior to publication on May 5, 2026
Inducement stock options29,760 sharesAggregate options granted May 4, 2026 to two non-executive employees
Inducement RSUs22,320 sharesAggregate restricted stock units granted May 4, 2026
Option vesting term4 years25% after one year from May 4, 2026, then monthly vesting
RSU vesting term4 years25% on each anniversary of May 4, 2026
First-year cliff25%Portion of options and RSUs vesting on first anniversary
52-week range$12.59–$47.6552-week low and high before this news
Market cap$2,444,700,318Equity value prior to this announcement
Market Reality Check
Price:$29.65Vol:Volume 821,185 is below t...
normal vol
$29.65Last Close
VolumeVolume 821,185 is below the 20-day average of 1,124,555 (relative volume 0.73x).normal
TechnicalPrice $29.28 is trading below the 200-day MA of $31.07, about 38.55% under the 52-week high and 132.57% above the 52-week low.
Peers on Argus
MLYS was up 1.33% pre-news while close peers showed mixed moves (e.g., IMVT, VKT...
1 Up1 Down
MLYS was up 1.33% pre-news while close peers showed mixed moves (e.g., IMVT, VKTX, CRNX down; SLNO slightly up). Momentum scanner peers were split, with 1 up and 1 down, supporting a stock-specific backdrop.
FDA acceptance of NDA for lorundrostat and topline Explore‑OSA trial results.
Pattern Detected
Recent news has produced mixed reactions: clearly positive regulatory/clinical updates have sometimes sold off, while other announcements have seen both gains and declines.
Recent Company History
Over the last few months, Mineralys issued several notable updates. In March 2026, the company announced FDA acceptance of the NDA for lorundrostat with a PDUFA date of December 22, 2026, alongside mixed but clinically meaningful Explore‑OSA results. Q4 and full‑year 2025 results highlighted cash and investments of $656.6 million supporting operations into 2028. The company also reported repeated inducement equity awards and a new Chief Legal Officer hire. Today’s additional inducement grants fit this ongoing pattern of equity-based hiring and retention activity.
Market Pulse Summary
This announcement details standard inducement stock option and RSU grants totaling 52,080 shares to ...
Analysis
This announcement details standard inducement stock option and RSU grants totaling 52,080 shares to two new non‑executive employees under the 2025 Employment Inducement Incentive Award Plan. The awards vest over four years with a 25% first‑year cliff, consistent with prior Mineralys disclosures. In the context of recent FDA and NDA milestones and insider trading activity, investors may monitor ongoing equity-based compensation, hiring trends, and future clinical or regulatory updates as key drivers.
Key Terms
chronic kidney disease, obstructive sleep apnea, restricted stock unit, stock option, +2 more
6 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
restricted stock unitfinancial
"inducement restricted stock unit awards covering an aggregate of 22,320 shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock optionfinancial
"granted inducement stock option awards covering an aggregate of 29,760 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Nasdaq Listing Rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, announced today that on May 4"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
AI-generated analysis. Not financial advice.
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on May 4, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 29,760 shares and inducement restricted stock unit awards covering an aggregate of 22,320 shares of Mineralys common stock to two new non-executive employees.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the options vesting on the first anniversary of the award’s vesting commencement date, May 4, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the four anniversaries of the award’s vesting commencement date, May 4, 2026. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
FAQ
What inducement awards did Mineralys Therapeutics (MLYS) grant on May 4, 2026?
The company granted inducement awards of 29,760 stock options and 22,320 restricted stock units. According to the company, the awards were issued to two new non-executive employees under the 2025 Employment Inducement Incentive Award Plan.
How do the Mineralys (MLYS) option awards vest after the May 4, 2026 grant?
Option awards vest over four years with 25% vesting after one year, then 1/48th monthly thereafter. According to the company, vesting is subject to continued service and the vesting commencement date is May 4, 2026.
What is the vesting schedule for the Mineralys (MLYS) restricted stock units granted May 4, 2026?
Restricted stock units vest over four years with 25% vesting on each anniversary. According to the company, the awards' vesting commencement date is May 4, 2026 and vesting is conditional on continued service.
Under what plan were the Mineralys (MLYS) inducement awards granted?
The awards were granted under the 2025 Employment Inducement Incentive Award Plan. According to the company, that plan authorizes equity awards to new employees as inducements to join Mineralys.
Why did Mineralys (MLYS) say the awards were granted under Nasdaq Listing Rule 5635(c)(4)?
The company said the grants qualify as inducement awards under Nasdaq Listing Rule 5635(c)(4). According to the company, that rule permits equity awards made as material inducements for newly hired employees.
